Elisa Agostinetto
@ElisaAgostinett
Followers
3,091
Following
1,658
Media
243
Statuses
1,209
MD, Medical Oncologist🇮🇹•Research Physician at @JulesBordet Institute in Brussels🇧🇪 Great interest in #BreastCancer and #ImmunoOncology
Joined November 2011
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
SEVENTEEN
• 1484737 Tweets
無料クーポン
• 169965 Tweets
DG X ORM KORNNAPHAT
• 99206 Tweets
連休明け
• 96747 Tweets
carat
• 81994 Tweets
अब्दुल कलाम
• 65344 Tweets
पूर्व राष्ट्रपति
• 45413 Tweets
アトラス彗星
• 43222 Tweets
FELIP TAKES ON BBPHSTAGE
• 30627 Tweets
JC BBPH MAINSTAGE
• 29822 Tweets
オーストラリア
• 28106 Tweets
ITZY WORLD IS STILL DIFFERENT
• 21415 Tweets
ミンギュ
• 18962 Tweets
金木犀の香り
• 17689 Tweets
#RokKłamstw
• 17651 Tweets
Mehmet Şimşek
• 17477 Tweets
JimmySea with PizzaMaru
• 17365 Tweets
うさぎだらけくじ
• 14635 Tweets
ジョシュア
• 13121 Tweets
スングァン
• 12713 Tweets
エスクプス
• 11914 Tweets
ドギョム
• 11464 Tweets
タワレコ
• 10280 Tweets
Pinned Tweet
Proud to share our last review now out on
@NatRevClinOncol
on the evolution of systemic therapy and trials for early
#breastcancer
🎯We can learn important lessons from the past to build the future!🚀
@JulesBordet
@Sorbonne_Univ_
@Inserm
@OncoAlert
7
38
168
#Immunotherapy
in Triple Negative
#breastcancer
: a new milestone in the treatment of
#TNBC
, but many open challenges exist (need of predictive biomarkers🎯, choice of better endpoints in clinical trials📈, longterm toxicity🤕) We discuss it in our review👇🏻
6
39
141
Out on
@JCO_ASCO
results of a randomized trial showing that women with early
#breastcancer
undergoing physical exercise and nutrition during neoadjuvant CT have⬆️pCR rate than those with usual care‼️
Provocative and intriguing data that require validation
4
45
134
How to manage pts with HER2+
#breastcancer
who become ➡️HER2-neg at surgery after neoadjuvant treatment? A subgroup analysis of
#KATHERINE
shows that post-neoadj T-DM1 in these pts was associated with⬆️IDFS compared to adjuvant trastuzumab
@OncoAlert
6
44
131
I am honored to receive a
@ConquerCancerFd
Merit Award for the second time in my life and to present two Poster Discussions at next
@ASCO
meeting!
Couldn’t be prouder to work at
@JulesBordet
with the best mentors ever
@MIgnatiadis
@E_de_Azambuja
10
5
111
What’s the cardiotoxicity❤️🩺associated with immune checkpoint inhibitors?⁉️Now out in EJC our meta-analysis of randomized controlled trials (35,337 pts!) in all solid tumors🧐
@eiger_daniel
@noam_ponde
@matteolambe
@E_de_Azambuja
@JulesBordet
@OncoAlert
5
38
107
Our last meta-analysis led by
@GuiNaderMarta
shows that ctDNA detection🧬🩸in early
#breastcancer
is associated with ⬆️ risk of recurrence, with mean lead time of 11 months
ctDNA detection had very high specificity for anticipating relapse
@OncoAlert
2
28
108
Adjuvant olaparib improves overall survival in high-risk BRCA-mut early
#breastcancer
(HR 0.68; 95%CI: 0.50-0.91; p=0.009)🚨
Just presented at
@myESMO
Virtual Plenary the OS data of
#Olympia
leading to FDA approval of adj olaparib✅ Great news for our BRCA patients!
@OncoAlert
0
32
103
I can’t be more proud to see our work published in
#JAMA
, one of the most important journals in medicine!
Congrats to
@matteolambe
for having led this great effort and international collaboration from all over the world
@OncoAlert
1
20
87
Prof Razavi at
#SABCS23
:
RB1 alterations are enriched in germline BRCA2 carriers, and BRCA2-mutated tumors tend to have worse PFS to CDK4/6i
To be noted that BRCA2 and RB1 are co-located on the same chromosome arm, and RB1 LOH is associated with resistance to CDK4/6i
@OncoAlert
2
37
97
Detection of ctDNA post-NACT in pts with early breast cancer is associated with disease relapse🚨Our Poster is now out at
#SABCS21
Here is a summary of the main results👇🏻1/8
2
20
91
We present at
#ESMOBreast21
our TiP ROSALINE✨a neoadjuvant study of targeting ROS1🎯with endocrine therapy in lobular breast cancer🙌🏻10 participating centers in Belgium🇧🇪&France🇫🇷Looking forward to providing new good options for pts with lobular breast cancer🙏🏻
@OncoAlert
@myESMO
2
32
91
My first
@ASCO
in presence has been an amazing experience!🇺🇸 Presenting 2 Poster Discussions on
@ASCO
stage and meeting so many colleagues and friends made my
#ASCO23
unforgettable. I am proud to work and collaborate with such wonderful people and be part of
@JulesBordet
🇧🇪team🙌🏻
7
3
92
CDK4/6i and PI3Ki break into HER2+ breast cancer🎯We discuss these new promising treatment strategies approaching the setting of HER2+ disease in our review
@EJCI_News
@Nader_Guilherme
@matteolambe
@E_de_Azambuja
@OncoAlert
2
37
89
What’s the risk of cardiotoxicity associated with Immune-Checkpoint Inhibitors?❤️🩺
We presented at
#ESMOImmuno20
our meta-analysis including 80 randomized clinical trials (35,337 pts!) Check it out!👇🏻
@eiger_daniel
@matteolambe
@noam_ponde
@E_de_Azambuja
@OncoAlert
4
21
90
Cardiotoxicity💔of immune checkpoint inhibitors is a rare but possibly fatal complication🚨‼️Increasing awareness and further investigation are needed🔎 Now out in BJMO our review👇🏻
#Immunotherapy
#CardioTwitter
@E_de_Azambuja
@mybsmo
2
25
88
Blinded independent central review (BICR) in clinical trials: is it really needed⁉️
In this meta-analysis out in
#EJC
we found no difference in PFS by BICR vs. by local assessment
➡️BICR⬆️costs and complexity in clinical trials
Free link👇🏻
@OncoAlert
4
25
85
Now out in
@SpringerNature
#CurrentOncologyReports
our review on Emerging Therapeutics for patients with Triple-Negative Breast Cancer🔥 Many thanks to this great team
@eiger_daniel
@kevinpunie
@E_de_Azambuja
🙌🏻🙌🏻🙌🏻
@OncoAlert
@mybsmo
Read it here:
7
28
85
The most provocative work from
#ESMO22
is now published in
@JCO_ASCO
:
Peritumoral lidocaine injection is associated with ⬆️survival in early
#breastcancer
Mechanisms are unclear, there is some preclinical rational, and it is an easy, cheap intervention👇🏻
0
28
83
Now out at
#ESMO22
the preliminary results of our PUCCINI study: early metabolic response by PET is associated with progression-free survival in patients with HR+,HER2-neg
#breastcancer
treated with CDK4/6i+ET.
@MarianaBrandao0
@E_de_Azambuja
@OncoAlert
@myESMO
1
16
76
#physicalactivity
beneficial for
#immunotherapy
? 🏃🏼♀️🏋🏽♀️
In this paper on
@JNCI_Now
being physically active at start of checkpoint inhibitors was associated with⬇️toxicity and ⬆️survival
Kudos to our Dutch colleagues 🇳🇱 for this interesting study!
@OncoAlert
1
18
74
Interesting news in HER2+
#breastcancer
with brain mets 🧠➡️Roche, with HER2 franchise under pressure, focuses on ZN-A-1041, a new HER2-targeting agent able to pass the blood-brain barrier and penetrate the 🧠
Ph1 trial is about to start⏱️
@OncoAlert
1
19
72
What’s the role of TILs🔬 in non-invasive breast cancer?⁉️Our meta-analysis now out in
@TheBreastOnline
shows association between ⬆️TILs and local recurrence‼️and with more aggressive characteristics (TNBC,HER2+,high grade and necrosis)
@OncoAlert
1
29
69
Now out our review on ctDNA in
#breastcancer
🧬🩸
We discuss its role in the metastatic setting, where it can identify targetable alterations💊 and in the early setting, to identify disease relapse before imaging🩻
@Nader_Guilherme
@MIgnatiadis
@OncoAlert
1
23
68
I am very honored to receive a
@GileadSciences
#BreastCancer
Research Award at the Annual Meeting of the Belgian Society of Medical Oncology🇧🇪 and to support research on
#lobular
breast cancer within the investigator-driven
#ROSALINE
study🙏🏻
@mybsmo
@OncoAlert
@LobularBCA
Congratulations to
@ElisaAgostinett
from
@JulesBordet
(with the mentorship of
@MIgnatiadis
) for receiving a Gilead award grant at the
@mybsmo
Annual Meeting 2023.
1
4
23
7
7
67
Un grande onore essere premiata anche quest’anno con un
@ConquerCancerFd
@ASCO
Merit Award dalla società americana di oncologia medica per la nostra ricerca sul carcinoma mammario.
Un grande grazie ai miei mentori
@E_de_Azambuja
@MIgnatiadis
7
2
67
Detection of circulating tumor DNA🧬 post-neoadjuvant CT in pts with early breast cancer is associated with disease relapse🚨Looking forward to presenting our prospective study at
#SABCS21
Stay tuned!
#LiquidBiopsy
#BreastCancer
#ctDNA
0
11
66
CDK4/6 inhibition in HR+ early breast cancer: are we putting all eggs in one basket?⁉️🧺 Take a look at our editorial now published on ESMO Open👀
@E_de_Azambuja
@OncoAlert
5
21
67
It is a real honor to receive an
@ASCO
Merit Award🙏🏻A huge thanks to my outstanding mentors
@matteolambe
and
@E_de_Azambuja
and all co-authors of this important project!! We will present it soon at
#ASCO21
🔜
@ASCO_pubs
@ConquerCancerFd
@JulesBordet
14
8
66
Thank you
@Medi_Mix
for highlighting our PALLAS sub-analysis on drug-drug interactions between palbociclib and proton pump inhibitors 💊 from
#SABCS23
@SABCSSanAntonio
@OncoAlert
2
10
66
#Immunotherapy
in HER2+ BC is an intriguing field under investigation. We discuss it in our review👇🏻with some of the top🇮🇹experts in
#breastcancer
:
@FilippoMontemu1
@puglisi_fabio
@CarmenCriscit
@BianchiniGP
@delmastro_lucia
Alberto Zambelli et al.
3
23
66
Does ctDNA🧬detection predict recurrence in patients with early
#breastcancer
? Our study now out in
@JCOPO_ASCO
provides an additional step in understanding the role of
#liquidbiopsy
🩸to early detect disease relapse‼️
@MIgnatiadis
@NateraOncology
1
22
62
Out in
@TheLancetOncol
:
Low dose olanzapine is non-inferior to standard dose in antiemetic efficacy🤢 and reduce somnolence🥱in pts receiving CT
Important findings on a low-cost intervention that is practice-changing with global applicability
@OncoAlert
3
21
64
Adjuvant CDK4/6i for early
#breastcancer
: how to choose wisely⁉️
In this work we discuss the most recent findings from
#MonarchE
and
#NataLEE
trials and put them in perspective for potential use in clinical practice
@Lucarecco
@E_de_Azambuja
@OncoAlert
1
18
63
Out in
@Nature_NPJ
Breast a nice review on the selection of appropriate biomarkers to monitor the effectiveness of ovarian function suppression with GnRH agonists in ER+
#breastcancer
➡️Estradiol levels remain the biomarker of choice
@OncoAlert
1
16
62
What a
#SABCS23
!!!
1️⃣My first oral presentation on
@SABCSSanAntonio
stage
2️⃣The results of our global academic effort presented in the General Session and published on
#JAMA
3️⃣New data with⬆️impact for
#breastcancer
patients
❤️to all colleagues and friends who make this possible
0
8
61
Important findings published in
@Nature_NPJ
Breast: 54% of HER2-null primary breast cancer have detectable HER2 expression in subsequently resected brain metastases
➡️HER2 expression can be heterogeneous across different lesions‼️
@OncoAlert
4
15
59
Out in
@Nature_NPJ
Breast: real-world🌎 study from a large cohort (n=5910) of pts with HR+/HER2-
#breastcancer
🔸ESR1 alterations were⬆️in secondary vs. primary endocrine resistance
🔹TP53 alterations were⬆️ in primary vs. secondary resistance
@OncoAlert
1
27
58
Happy to receive a
@myESMO
Merit Travel Grant for the work we will present at the upcoming
#ESMOBreast24
!
🔜See you all in Berlin🇩🇪 ✈️
@OncoAlert
6
3
59
Finally..we are Medical Oncologists! Super proud of having completed these 5 yrs of residency with the best colleagues and friends I could have ever imagined❤️Many thanks to our mentors and to our Director Prof
@LorenzaRimassa
@HUNIMED
#oncology
#womenforoncology
#CancerResearch
8
0
57
It is a real honor to share our work now published in
@TheLancetOncol
about the management of endocrine therapy’s AEs in breast cancer patients: a further step to improve patient quality of life👩🏼⚕️👩🏻💼👨🏻⚕️👩🏽💼
@AliceFranzoi
@MartaPerachino
@matteolambe
@E_de_Azambuja
@OncoAlert
Excited to share our
@TheLancetOncol
review on how to manage side-effects of adjuvant
#EndocrineTherapy
in
#BreastCancer
patients
@AliceFranzoi
@ElisaAgostinett
@MartaPerachino
@E_de_Azambuja
@delmastro_lucia
@inesvazluis
@YoungStrongDFCI
@OncoAlert
#bcsm
10
69
215
0
11
56
Nice review out in
#TheBreast
summarizing the best and not-to-miss advancements in
#breastcancer
in 2023
Useful resource for all HCP!
Proud to see cited here our work led by
@matteolambe
on pregnancy after breast cancer in young BRCA carriers🤰🏼
@OncoAlert
0
23
56
Out in
@Annals_Oncology
the pooled
#ctDNA
analysis from the
#MONALEESA
studies:
➡️ERBB2, FAT3, FRS2, MDM2, SFRP1, and ZNF217 alterations had⬆️sensitivity to ribo✅
➡️ANO1, CDKN2A/2B/2C, and RB1 alterations and high TMB had⬇️sensitivity ❌
@OncoAlert
1
18
55
Out in
@JAMAOnc
the results of
#NeoPACT
, phase II trial of Neoadjuvant Pembrolizumab, Carboplatin, Docetaxel in TNBC (n=115)
Encouraging activity of this anthra-free regimen:
➡️pCR 58%
➡️3y-EFS 86% (98% in pCR‼️)
➡️confirmatory phase 3 needed
@OncoAlert
1
14
53
Great presentation by
@E_de_Azambuja
on extended adjuvant endocrine therapy for HR+,HER2-neg early
#breastcancer
at
#ESMO22
: decision should be based on recurrence risk, tolerability, AEs and patient preferences. Online tools (BCI, CTS5) may help!
@OncoAlert
@myESMO
0
15
52
Final results from the randomized, ph3
#ASCENT
study out in
@JCO_ASCO
Sacituzumab govitecan ⬆️ PFS (mPFS 4.8 v 1.7 months; HR 0.41) and ⬆️ OS (mOS 11.8 v 6.9 months; HR 0.51) over treatment of physician choice
@OncoAlert
0
17
52
CDK4/6i in (post-neo)adjuvant setting for HR+/HER2- early breast cancer‼️Our meta-analysis shows:
🔸a trend for benefit in iDFS
🔸no association with benefit in DRFS
🔸higher toxicity and tx discontinuation
➡️Longer follow-up is needed!
AddThis | Home
4
16
50
#SABCS23
General Session2️⃣:
Large EBCTCG Meta-analysis on axillary management in patients with early breast cancer (n=20,273‼️)
Clear and important conclusions by the authors⬇️⬇️⬇️
@OncoAlert
@SABCSSanAntonio
0
10
37
Just presented at
@myESMO
Virtual Plenary the updated survival data of
#APHINITY
with 8.4 yrs of follow-up of adjuvant pertuzumab and trastuzumab in pts with HER2+
#breastcancer
No benefit for node-neg disease, while node+ continues to derive benefit from pertuzumab
@OncoAlert
0
11
49
Interesting data at
#ESMO22
on anthracycline-induced cardiotoxicity in breast cancer pts carrying mutational signature of HRD: Germline mutations in HRR seem to ⬆️cardiomyocytes sensitivity to anthracyclines
@OncoAlert
@myESMO
0
19
48
Great presentation by
@matteolambe
about ovarian function suppression in premenopausal women with early breast cancer🔝🔝🔝👏🏻👏🏻👏🏻
#e_ESO
0
14
50
Is it time to adopt CDKi in adjuvant setting??🤔🧐Great presentation by
@E_de_Azambuja
at 9th Asia-Pacific Breast Cancer Summit
#APBCS2021
@APBCS
➡️Longer follow-up and optimal patient selection are needed☝🏻
0
14
47
Now out in
@Annals_Oncology
our editorial on the results of the pooled
#ctDNA
analysis from the
#MONALEESA
studies
We discuss some insights on the largest ctDNA analysis to date on genomic alterations and efficacy of CDK4/6i👇🏻
@MIgnatiadis
@OncoAlert
0
15
48
In
@JCO_ASCO
the updated results (6.9y f.u.) of the Anthracyclines in EBC trials
➡️Noninferiority in IDFS of the non-anthra CT not reached
➡️RFI favors anthra (driven by TNBC)
➡️No difference in OS; ⬆️leukemias &non-BC deaths in anthra group
@OncoAlert
1
17
48
I am very happy and proud to have participated as speaker at the
#Focus
in BreastCancer, an Italian excellent event to discuss about
#breastcancer
with many Italian friends and colleagues. Thanks to Prof
@puglisi_fabio
for organizing such an amazing event in the beautiful Udine🇮🇹
0
2
48
Does the prognosis of TNBC patients change if we treat them according to their molecular subtype (LAR, IM, BLIS, MES)⁉️
Intriguing results from this ph2 trial in
@TheLancetOncol
showing⬆️PFS in the subtyping-based treatment group
🔜Ph3 underway
@OncoAlert
0
16
47
Proud to share the results of our phase I/II trial SYNERGY now out in
@NatureComms
👇🏻
Our investigator initiated study sponsored by
@JulesBordet
tested chemo immunotherapy +/- the antiCD73 oleclumab in 1st line TNBC
Congrats to
@LauBuisseret
!
@OncoAlert
1
12
47
Now out our meta-analysis on mortality in pts with cancer and SARS-CoV-2 infection🦠
➡️high mortality (CFR 25%)❗️
➡️comparatively higher mortality for pts with lung cancer🫁
➡️preventive measures are needed including early access to COVID vaccination‼️
1
25
47
Out in
@Annals_Oncology
EFS benefit according to RCB in KEYNOTE-522
Addition of pembro resulted in⬆️EFS in RCB-0, -1, and -2 categories, with the greatest benefit in RCB-2
No benefit in RCB-3, but a very small subset of pts (n=66) had RCB-3
@OncoAlert
0
15
47
Now out in
#ClinicalBreastCancer
our subanalysis of the
#CLEOPATRA
study led by
@VeroniqueDebien
showing that patients with radiological complete response at 1️⃣st disease re-evaluation have significantly ⬆️ survival
@OncoAlert
1
20
46
📢Unmissable paper now out in
@Annals_Oncology
with the last
@myESMO
guidelines in early
#breastcancer
‼️
@OncoAlert
0
11
46
#ESMO22
: brilliant
@Mattia_Rediti
on the Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial: HER2+ BC is heterogeneous, with ⬆️outcomes in luminal and immune-enriched
@OncoAlert
0
11
46
Out in
@JAMAOnc
a cohort study on 4332 women BRCA carriers🧬 (without prior history of cancer)
➡️ Prophylactic oophorectomy was associated with significant⬇️ in all-cause mortality
@OncoAlert
0
15
45
Lobular breast cancer is different from ductal breast cancer and requires dedicated clinical trials🎯
ROSALINE is an investigator-driven neoadjuvant trial testing the ROS1 inhibitor Entrectinib + ET in patients with
#lobular
#breastcancer
in 🇧🇪 and 🇫🇷
1
13
44
Useful and very pratically-oriented paper out in
@ESMO_Open
on the management of infusion-related adverse reactions in oncology
@OncoAlert
0
11
43
Mini-oral session at
#SABCS23
Intriguing preclinical data on a new PI3K inhibitor that does NOT cause hyperglycemia and hyperinsulinemia
Clinical validation needed
@OncoAlert
@SABCSSanAntonio
0
8
32
This is
#PinkOctober
, a month dedicated to increase awareness on
#breastcancer
🎀
Proud to be part of
@JulesBordet
team and to work everyday with extraordinary colleagues and mentors to help fight against breast cancer🏩
2
7
40
Looking forward to presenting our work at
#SABCS23
at the Spotlight Discussion on HER2+
#breastcancer
- exploiting tumor biology to escalate/de-escalate therapy. Intriguing data from the APHINITY trial!
@OncoAlert
@BIGagainstBC
@JulesBordet
@VJOncology
@SABCSSanAntonio
0
12
44
Super
@matteolambe
on stage for General Session2️⃣ presenting the results of one of the most awaited studies of
#SABCS23
(and simultaneously published in
#JAMA
‼️)
Pregnancy after breast cancer in women with BRCA mutations is safe🤰🏼👶🏻
@OncoAlert
2
19
43
Out in
@TheLancetOncol
a comprehensive analysis of patients with
mismatch-repair deficiency syndrome🧬showing very young age at diagnosis, high cancer burden and unique genomic landscape
Timely diagnostic assays and precision approaches are🔑
@OncoAlert
0
18
42
Out in
@Nature_NPJ
Breast the final efficacy results of the
#PATRICIA
trial on pertuzumab + high-dose trastuzumab (6mg/kg weekly) for HER2+ breast cancer patients with brain metastases 🧠
Confirmed ORR (CNS): 11%
Median CNS-PFS: 4.6 months
@OncoAlert
0
14
42
Interesting article on
@Annals_Oncology
describing alterations in PARP inhibitor resistant advanced breast cancer by longitudinal profiling
BRCA1/2 reversion mutations found in ctDNA in 60% of patients that develop resistance‼️
@OncoAlert
1
19
41
#MCCRWorkshop
has been an amazing experience, that went far beyond my expectations. High-level science, precious help to build our study protocols and great friends and colleagues to share this journey with. Thanks to the organisers
@EORTC
-
@myESMO
-
@AACR
and to our🔝 faculty!
0
3
41
Interesting study in
@NatureMedicine
showing that different individuals have different metabolic response to identical meals 🥗🍝🍗
➡️interesting findings that support personalized diet strategy
2
8
40
What is the real-life cardiotoxicity associated with s.c. versus i.v. trastuzumab?❤️💔🩺 We investigated it under the lead of
@desanctis_rita
in our cohort at
@HumanitasMilano
and published in
@TheBreastOnline
➡️check it out!!
@HUNIMED
@OncoAlert
3
9
40
Now out in
@Nature_NPJ
Breast the final results of
#ZEPHIR
, phase 2 trials conducted in🇧🇪and 🇳🇱 and sponsored by
@JulesBordet
➡️Molecular imaging with HER2 PET-CT predicts lack of T-DM1 response in advanced HER2-positive breast cancer
@OncoAlert
0
19
40
Cancer Statistics 2024 in 🇺🇸 are out now!
✅ Cancer mortality continues to ⬇️ thanks to reductions in smoking, earlier detections, and improved treatments;
✖️However, incidence ⬆️for 6 of the top 10 cancers, including
#breastcancer
@OncoAlert
0
13
40
At
#SABCS23
the first Poster session is starting now!
Pass by to check our Poster PO1-01-08:
Sub-analysis of the randomized phase 3 PALLAS trial on the drug-drug interactions between palbociclib and proton pump inhibitors!💊
@JulesBordet
@OncoAlert
@BIGagainstBC
@ABCSGVienna
3
10
39
Nice editorial out in
@JCO_ASCO
on the design, analysis, and reporting of research that involves real-world data 🌎
Real world evidence is so important yet subject to biases and limitations that must be acknowledged and addressed!
@OncoAlert
1
14
39
Out in
@Annals_Oncology
: a pilot study shows that FES-PET can predict response to endocrine therapy in pts with ER+HER2- MBC
Molecular imaging is getting increasing importance in dissecting the heterogeneity within a
#breastcancer
subtype‼️
@OncoAlert
0
12
39
Un grande onore aver presentato a
#AIOM21
i risultati del nostro lavoro nella sessione
#breastcancer
con
@BlondeauxEva
e
@MartaPerachino
🙌🏻Grazie ai moderatori
@FilippoMontemu1
Valentina Guarneri e a
@matteolambe
per la sua guida e supporto. Let’s fight cancer together!
@AIOMtweet
4
6
36
Out in
@NatureMedicine
results of the
#DAISY
study, testing T-DXd in tumors with different HER2 expression (positive, low, zero).
Activity observed in the 3 cohorts➡️Besides HER2 expression, additional mechanisms may determine T-DXd efficacy
@OncoAlert
0
7
37
At
#SABCS23
discussion on the late breaking approval of
#capivasertib
in
#breastcancer
, trying to answer the question: is the benefit observed both in the biomarker positive and negative population⁉️
Excellent slide explaining how to select the favored population ⬇️
@OncoAlert
2
8
37
Benefit of physical exercise: repeating does good! 🏋🏼♀️🏃🏼♀️🚴🏼♀️
This large study at
#SABCS23
shows significant benefit of supervised exercise intervention during palliative treatment on metastatic BC patients’ fatigue, HRQoL, and other clinically relevant outcomes
@OncoAlert
0
17
37
Great
@matteolambe
awarded with the Best Mentor Award at
#MCCRworkshop
!!!! So well deserved 🤩🤩🤩
0
2
36
Do brain mets🧠hamper the access to clinical trials?💊
A letter in
@JAMAOnc
shows that the number of trials excluding pts with brain mets is decreasing📉across years. But pts with brain mets and on steroids are still underrepresented in IO trials
1
14
36
Important meta-analysis in
@Nature_NPJ
Breast shedding light on one of the biggest unmet needs in breast oncology
Lobular tumors are largely disregarded in most trials with poor representation and documentation
@OncoAlert
2
11
36
Excellent
@myESMO
webinar on
#breastcancer
in hereditary predisposition syndrome🧬 Clinical case from real-world🌎
+ discussion of guidelines w/ C. Sessa, S. Paluch-Simon,
@matteolambe
&
@bpellegrino89
➡️Testing,screening, risk⬇️surgery,surveillance are key issues!
@OncoAlert
0
6
35
Have you ever heard of
#VISTA
?👀 VISTA is an immune checkpoint and a promising target for cancer immunotherapy🎯We discuss its role in our review led by
@M_Tagliamento
👇🏻👇🏻👇🏻
0
9
35
Out in
@JAMAOnc
a pooled analysis exploring tumor intrinsic subtypes in 3 trials on HER2+ EBC
pCR was associated with EFS in
HER2-E and basal, but not luminal subtypes
Benefit of dual HER2 blockade (T+L) was restricted to HER2-E tumors
@OncoAlert
2
20
34
Now out our abstract at
#ASCO21
about the prognostic performance of PREDICT+ in pts with HER2+ early breast cancer!👇🏻Happy and honored that our work was awarded with a Merit Award🏆Thanks to
@matteolambe
@E_de_Azambuja
@BIGagainstBC
& all amazing team🙌🏻
0
9
34
What are the new treatment strategies available in the post-neoadjuvant setting for patients with early
#breastcancer
⁉️
We discuss it in our new review👇🏻👇🏻👇🏻
@LauBuisseret
@E_de_Azambuja
@OncoAlert
@MDPIOpenAccess
0
14
33
Out in
@JCO_ASCO
the new ASCO–Society of Surgical Oncology Guidelines on Germline Testing in Patients With
#BreastCancer
‼️
BRCAmut testing should be offered to ALL newly diagnosed patients ≤65 years and to selected patients >65 years
@OncoAlert
0
8
33
Amazing discussion on Molecular Tumor Board addressing important issues ➡️patient selection for NGS, impact of NGS on clinical outcomes, access to clinical trials across EU, and future perspectives!! Network is the key🗝
@aftimosp
@MOliveira000
@kevinpunie
@TeresaSAmaral
@myESMO
0
6
32
Now out in
@JCO_ASCO
the updated survival data of
#MonarchE
➡️adjuvant abema is associated with absolute ⬆️ in 5-year IDFS and DRFS rates of 7.6% and 6.7%, respectively
➡️ OS still immature, numerically⬆️ but not statistically significant
@OncoAlert
0
9
32
Out in
@Annals_Oncology
our editorial on the KEYNOTE-522 analysis of event-free survival by residual cancer burden (RCB)
Does RCB help tailor adjuvant treatment ⁉️
@OncoAlert
@MIgnatiadis
@LauBuisseret
@lab_kok
0
11
32
Results of ROSET-BM trial are now published in
@Nature_NPJ
Breast - important data on activity of T-DXd in patients with HER2+
#breastcancer
and brain metastases and/or leptomeningeal disease🧠
Benefit shown in intracranial ORR/PFS, PFS, and OS
@OncoAlert
0
9
32
Results from the KENDO trial, testing CDK4/6i+ET vs. CT+ET in aggressive HR+/HER2- aBC
The study was closed early after 49 pts due to slow accrual
➡️Still, CDK4/6i seem to⬆️PFS vs. CT
➡️Basal-like PAM50 subtype had the worst PFS with CDK4/6
@OncoAlert
2
10
32